The combination of Gal-3 with soluble suppression of tumorigenicity 2 (sST2), another fibrosis/remodeling biomarker, provides even greater predictive power for adverse LV remodeling and HF events (Gagno et al., 2019). The gene discussed is LGALS3; the disease is hydrops fetalis.